EPISODE · Nov 24, 2025 · 19 MIN
ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma
from PharmaTalkRadio · host Conference Forum
About this podcast:This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center. Dr Rosenberg focuses on: The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancerThe potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune responseEnfortumab vedotin, an ADC targeting Nectin-4For more information, go to IO360summit.com.
What this episode covers
About this podcast:This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center. Dr Rosenberg focuses on: The background and previous data of immune checkpoint blockade as monotherapy and in combination with chemotherapy, in urothelial cancerThe potential role of Immunogenic Cell Death and whether it has a clinical impact on patient care and creating an anti-tumor immune responseEnfortumab vedotin, an ADC targeting Nectin-4For more information, go to IO360summit.com.
NOW PLAYING
ADCs, Chemotherapy, and Checkpoint Blockade in Urothelial Carcinoma
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.